Gastroscopic evaluation of anti-inflammatory agents* I CARUSO, G BIANCHI PORRO Summary and conclusions Gastroscopy was performed in 164 patients with rheumatoid arthritis (RA) and 85 with osteoarthritis (OA) to assess the effects of anti-inflammatory agents on the stomach. The main criterion for entry into the trial was the absence of active gastric lesions on pretreatment endoscopy. The patients were divided into groups to receive one of 12 anti-inflammatory drugs or combinations of these. Gastroscopy repeated at three to six and at 12 months disclosed gastric lesions in 78 cases (31%), patients in both disease categories being similarly affected. Lesions occurred in 41 of the 177 patients (23%) receiving a single drug and in 37 of the 72 (51 %) receiving combined treatment. All the anti-inflammatory drugs caused gastric damage, the greatest offender being aspirin (13 out of 26 patients) and the least sulindac and diflunisal (two out of 19 (11%) and two out of 20 (10%) patients respectively). Corticosteroids caused gastric damage in only three out of 21 patients (14%), a lower incidence than expected.
The indiscriminate prescribing of anti-inflammatory drugs to patients with OA is to be deplored. A lack of correlation between the patients' subjective complaints of gastric discomfort and the gastroscopic findings emphasises the unreliability of patients' complaints and the importance of gastroscopy in assessing gastric tolerance. It was not possible to assess minimal prescribing doses or minimum periods of treatment below which gastric damage may be guaranteed not to occur.
Introduction
Gastric injury is a major and undesirable side effect of most anti-inflammatory agents, be they corticosteroids or nonsteroidal anti-inflammatory drugs.1'2These drugs are generally thought to be capable of aggravating existing gastric disease and in some instances of actually causing peptic ulceration.'-8 Evidence exists suggesting that non-steroidal anti-inflammatory drugs, particularly aspirin, can cause acute gastric erosions and microbleeding, [9] [10] [11] [12] but the results obtained in clinical trials and epidemiological studies designed to prove the existence of such a relation have not been conclusive. [13] [14] [15] In clinical trials with patients suffering from rheumatoid arthritis (RA) and treated with various anti-inflammatory drugs the incidence of peptic ulcer has ranged from 4.6o016 to 310%.17 An incidence of 31% would appear to favour the hypothesis that patients with arthritis are particularly prone to develop peptic ulcer,17 18 but this is controversial.
We designed this study to determine the incidence of peptic ulcer in patients with RA or osteoarthritis (OA); the incidence of acute gastric erosions after prolonged treatment with various anti-inflammatory drugs (single-and multiple-drug treatment); and the relation between the gastric damage observed during single-drug treatment and the drug dosage, duration of treatment, history of peptic ulcer, and sex of the patient.
Patients and methods
We chose for our study 249 men and women suffering from chronic RA (164 patients; 40 men, 124 women) or OA (85 patients; 28 men, 57 women), most of whom had received prolonged treatment with anti-inflammatory drugs. Table I shows the age and sex distributions of the patients. We were unable to include a control group because of the clinical conditions of all the patients studied (all had joint pain or impairment of joint function, or both). Moreover, the purpose of the trial was to assess the effect of long-term treatment, and such patients cannot be left untreated for a long time. tracks" and other evidence of trauma caused by a retreating endoscope were not recorded and any abnormalities could, with greater certainty, be attributed to the drugs ingested.
Patients were seen at monthly intervals, when their general wellbeing, the state of affected joints, and any dyspeptic symptoms were assessed and noted. Results were assayed by the x2 test and Fisher's exact test.
Results
Fifteen of the 164 patients with RA (three men, 12 women; 900) and nine of the 85 with OA (five men, four women; 1100) showed signs of healed peptic ulcers on endoscopy before treatment (overall incidence 24 out of 249 patients; 1000o). Differences between men and women were not significant. Thirty-six patients (including the 24 mentioned above) had a clinical history of peptic ulcer or erosion, or both: 22 (seven men, 15 women) had RA and 14 (six men, eight women) OA. After three months' treatment gastric erosions were present in 41 of the 177 patients receiving a single drug (230') and in 37 of the 72 receiving multiple-drug treatment (5100), an overall incidence of 31%. In the 177 patients who received a single drug (table II) the incidence of gastric erosions or ulceration, or both, with each drug was as follows: aspirin (ASA) 5000 (13 patients); indomethacin 30°0 (six); ketoprofen 270 (three); naproxen 270" (three); diclofenac 2000 (two); ibuprofen 1800 (three); oxyphenbutazone 150O (two); corticosteroids 14 (three); sulindac 110O (two); diflunisal 100O (two); indoprofen 4001' (two); and corticotrophin nil. Thus aspirin, indomethacin, ketoprofen, naproxen, and diclofenac can apparently damage the gastric mucosa, while corticosteroids were better tolerated than expected. Too few patients were taking indoprofen and corticotrophin for any conclusions to be reached on these drugs.
When aspirin, which was associated with the highest incidence of gastric lesions, was taken as a reference and the other drugs compared with it the incidence of gastric lesions was significantly lower with corticosteroids, sulindac, and diflunisal (P < 0 01) and with oxyphenbutazone and ibuprofen (P < 0-05), but not with naproxen, ketoprofen, diclofenac, and indomethacin. Table IV shows the relations between gastric injury, daily dosage of drug given, and duration of treatment. Again the sample size precluded statistical evaluation, but some interesting trends were seen. In patients receiving aspirin the incidence of gastric lesions appeared to be higher in the higher-dosage group ( 3 g/day) than in the lowerdosage group. In the higher-dosage group most lesions were observed during the first month of treatment. A dose-dependent effect may also have existed with indomethacin: four out of eight patients taking over 100 mg/day developed gastric injury compared with two out of 12 receiving 100 mg daily. The patients receiving 100 mg daily, however, were all treated with suppositories, whereas in those receiving more than 100 mg/day the drug was administered by mouth and per rectum. In the patients receiving corticosteroids gastric lesions were observed only in those who had been taking more than 10 mg prednisone or equivalent daily for over six months. In the patients receiving ibuprofen no lesions were observed in 10 patients treated with 900 mg, patients with a history of ulcer or erosions, or both; but in only two of these patients did we observe, along with this recurrence, a new gastric ulcer that could unquestionably be attributed to drug treatment. A recurrence of peptic ulcer was observed in 11 (46%) of the 24 patients with healed peptic ulcers at pretreatment endoscopy (table VI) . There was no significant difference between men and women with either RA or OA in recurrence of gastric disease (table  VII) . 
Discussion
The overall incidence of endoscopically confirmed gastric lesions during treatment with anti-inflammatory drugs in this prospective study was 31 0. The incidences were similar in patients with OA (29%) and RA (32%h) (table III). The duration of disease did not appear to be an important predisposing factor (table III). The high incidence of gastric damage in patients with OA, a disease for which no particular susceptibility to gastric injury has ever been claimed, was most probably due to the increasing use of anti-inflammatory drugs by these patients.
The incidence of gastric injury ranged from 230°,0 in patients receiving a single drug to 51°% in patients receiving multipledrug treatment. Even though the patients receiving several drugs (mainly cortisone derivatives, aspirin, indomethacin, and ibuprofen) included those with the most severe disease, we believe that the concomitant administration of these drugs was directly related to the incidence of gastric damage. All these drugs have the same mechanism of action' 9-that is, they remove prostaglandin-supported defence mechanisms.
The tendency of rheumatologists to coadminister several drugs to reduce the cortisone dosage is justified only when such drugs have different modes of action and affect different stages of the inflammatory process. This, however, was probably not the case with the drugs in this study. The incidence of peptic ulcers per se was 10%, which is lower than the 14% observed in the general population.20 In addition, the number of new ulcers developing during this study was extremely low (two out of 249 patients). Most of the patients had already been receiving anti-inflammatory drugs for varying periods of time, so that this complication occurred in subjects who were possibly predisposed to it. The risk of recurrence of old ulcers, however, was high (46% -table VI). This finding emphasises even further the need for caution in treating rheumatic patients with a history of peptic ulcer. If it is true that the use of anti-inflammatory drugs is inevitable in most patients with RA, it is even truer that their use in OA should and can be strictly limited. Indiscriminately using combinations of these drugs is usually unjustifiable in this disease, particularly when a previous peptic ulcer is known or suspected.
In this survey aspirin and indomethacin were the two drugs most frequently associated with gastric toxicity (50% and 30% respectively). Aspirin given to six patients in doses exceeding 3000 mg/day ( Oxyphenbutazone (200-300 mg/day) and ibuprofen (ranging from 900 to 1200 mg/day) were slightly better tolerated than aspirin. We found that at "physiological" doses (5-7 mg of prednisone or equivalent/day) over long periods corticosteroids rarely cause endoscopically detectable gastric injuries, which agrees with the findings of Conn and Blitzer.21
The drugs best tolerated by the stomach appeared to be sulindac and diflunisal. The good gastric tolerance of sulindac might be related to its pro-drug property. In effect, it is absorbed in the gastric tract in the inactive form (sulfoxide) and subsequently metabolised in the liver into the active form (sulfide). This process would circumvent the inhibiting action of these drugs on gastric prostaglandins, which probably protect the mucosa. The relatively good tolerance of diflunisal, a derivative of salicylic acid, might be due to its increased pharmacological potency as compared with aspirin. In our experience22 750 mg of diflunisal is at least as effective as 3000 mg aspirin in treating OA.
The incidences of gastric lesions associated with the various drugs were compared with the incidence associated with aspirin (the highest seen); only corticosteroids, diflunisal, and sulindac differed significantly from aspirin.
Another important feature in assessing side effects of these drugs is the presence of subjective symptoms related to objectively proved gastric lesions. In the group receiving a single drug 17 
Patients and methods
We studied 20 insulin-dependent diabetics (12 female and 8 male) undergoing surgery. The criteria for selection were that each patient would require a general anaesthetic but no intravenous fluids, and that he would be eating or drinking by the evening of the operation.
The operations performed included photocoagulation in seven patients, removal of a lower-segment caesarean section scar, liver biopsy in a child, teeth extraction in two patients, cleaning and debridement of a bed sore, cauterisation of vulval warts, antral washout, various other ENT procedures in four patients, metatarsal osteotomy, and removal of a retinal detachment implant. We also studied a control group of eight insulin-dependent diabetics (five female and three male) undergoing similar types of surgery (three photocoagulation, two teeth extraction, one antral washout, and two orthopaedic drainage procedures).
The patients in both groups were longstanding diabetics (duration of diabetes seven to 50 years). All apart from one in the test group had been receiving insulin from the time of diagnosis of diabetes. Sixteen of the patients in the test group and seven controls had had at least one episode of ketoacidosis during their lives, and in all the diabetes had been diagnosed before the age of 30 years. The mean (±SD) daily requirement of insulin in the test group was 48-2±15 2 (range 24-80) units and in the controls 44-5 ± 15-2 (range 24-72) units. The mean age of the patients in the test group was 41-8±17-1 (range 9-71) years and in the control group 44-1 ±16-8 (range 13-65) years.
The regimen used for the test group is as follows. Only soluble insulin is given on the evening before operation and the mediumacting insulin omitted. The mini-pump is set up first thing in the morning and blood glucose concentrations measured. The minipump is so called because it is light and portable and may be attached by a strap around the arm or by a holster for long periods; it is a miniature version of larger insulin infusion pumps used in acute diabetic emergencies. There are several models: we used the Mill Hill Infuser (fig 1) 
